



Delaware Judiciary Town Hall

Alfred E. Bacon, III MD FACP

September 10, 2021

COVID 19- Topics

- Current Delaware/National Data
- The Delta Variant
- Vaccine comparisons
- Children/ Pregnancy
- “Long Haul” and post COVID syndromes
- Vaccine safety, masking, social distancing
- Current Delaware Judiciary Protocols

76.1%

**Delawareans 18+ With at
Least 1 Vaccine Dose**

Data Source - CDC

1,116,666

Vaccines Administered

1,880

Total Deaths

378

New Cases
7-day Average


220

Current Hospitalizations

7.4%


Positive Tests
7-day Average

Daily Trends in Number of COVID-19 Cases in The United States Reported to CDC



Percent of persons testing positive


Percent of tests that are positive



	New cases rate <i>(per 100,000 people)</i>	Percent of tests that are positive	Avg. daily hospitalizations <i>(per 100,000 people)</i>
08/21/2021 - 08/27/2021	255.4	7.2	20.4
08/14/2021 - 08/20/2021	235.7	7.2	14.4
08/07/2021 - 08/13/2021	170.6	6.6	10.4
07/31/2021 - 08/06/2021	117.2	5.1	5.6
07/24/2021 - 07/30/2021	68.5	3.9	3.6

Current Hospitalizations

Data are current as of 6pm the previous day. Last update: 09/06/2021



Daily infections and testing [↗](#)

Trend


Compare

Map

Estimated infections are the number of people we estimate are infected with COVID-19 each day, including those not tested.

Estimated infections | Confirmed infections | Tests

Scenario ⓘ | Projection X | Worse X | Masks X v



Hospital resource use [↗](#)


[Trend](#)

[Compare](#)

[Map](#)

Hospital resource use indicates how equipped a location is to treat COVID-19 patients for the **Current projection** scenario. Select **All beds** or **ICU beds** for descriptions of each measure.

All All beds ICU beds




Covid -19 Management

- Monoclonal Ab infusion
 - Combination agents
 - < 10 days post assay
- Remdesivir
- Steroids
- Immune blocking agents
 - Block inflammatory response
 - Supply issues

United States: 5/16/2021 – 8/21/2021

United States: 8/15/2021 – 8/21/2021 NOWCAST



USA

WHO label	Lineage #	Type	%Total	95%PI
Alpha	B.1.1.7	VOC	0.2%	0.0-0.7%
Beta	B.1.351	VOC	0.0%	0.0-0.2%
Gamma	P.1	VOC	0.1%	0.0-0.5%
Delta	B.1.617.2	VOC	98.8%	97.6-99.8%
	AY.2	VOC	0.2%	0.0-0.7%
	AY.1	VOC	0.1%	0.0-0.5%
Eta	B.1.525	VOI	0.0%	0.0-0.2%
Iota	B.1.526	VOI	0.0%	0.0-0.2%
N/A	B.1.621		0.3%	0.0-0.7%
	B.1.621.1		0.1%	0.0-0.5%
	B.1.628		0.1%	0.0-0.5%
Other	Other*		0.1%	0.0-0.5%

* Enumerated lineages are VOI/VOC or are circulating >1% in at least one HHS region during at least one two week period; remaining lineages are aggregated as "Other".
 ** These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates.
 # Sublineages of P.1 and B.1.351 are aggregated with the parent lineage and included in parent lineage's proportion. AY.3-AY.12 are aggregated with B.1.617.2

Children/Covid-19 (< 12 y old)

- 4.8 million children infected
- August 9% increase in children
- 11-20 % total
- 1.6-3.6 % of hospitalized
- 0.24 % of deaths

- AAP August 2021

Children/Covid-19

- unvaccinated adolescents- 10x higher admission rate
 - 20 % ICU admissions < 17 years old
 - admissions – up 5 fold since July
 - 23 % adolescent admissions to ICU
 - 9.8 % of admissions require mechanical ventilation
 - No affect on mortality
 - No clear predisposing “long Covid” events
- CDC (2 STUDIES)

Children /Covid -19 (<12 y old)

- Mild disease, asymptomatic
- Easily transmit without symptoms
- Co-illness- similar to adults
 - Obesity, asthma,
 - Down's , congenital diseases
- Multisystem inflammatory Syndrome- Covid (MIS-C)
 - Rash(diffuse),fever, Nausea vomiting
 - Lungs, heart,kidneys
 - Weeks after disease
 - Typical recovery (slow

- AAP August 2021

Vaccine Efficacy

- Measure vaccine success
 - Neutralizing antibody studies – test blood vs virus in test tube
 - Epidemiology – rates of illness compared by vaccine received
 - Measure antibody levels in patients post vaccine
- Hospitalizations
 - 90-98% of hospitalized are unvaccinated
 - Review “breakthrough “ cases hospitalized

Vaccine Efficacy - Delta

- "Moderna makes twice the Antibodies as Pfizer"
- 6-8 months post vaccine titers drop- both mRNA
- J and J – Ab levels remain high 8-12 months
- Goal- prevent severe dz, hospitalizations, death
- Overall- clinical , prevent illness
 - J and J 67%
 - Moderna 66-95 %
 - Pfizer 42-96 %
 - Mortality remains < 1% in all vaccinated humans

Vaccine Safety

- General malaise , fever, myalgia
- Multiple days
- 369 million doses nationwide
- Thrombosis syndrome- women 18-49
- Anaphylaxis –rare allergic
- GBS -rare neurologic reaction(< influenza)
- Myocarditis (mRNA vax)
- Death –unreported?
- Booster reactions?

Pregnancy/Covid- 19

- 105,000 pregnant women infected
- 18,000 hospitalized(17 %)
 - 6 fold more likely to be hospitalized
 - High percent critically ill
 - Induced labor- reduce maternal stress/optimize birth
- 25% ICU
- 124 deaths
- No increased miscarriages (first 6-10 weeks)
 - CDC August 2021

Pregnancy /covid - 19 vaccination

- 35,691 pregnant vax recipients
 - Myalgia, fever, pain locally
 - 3958 vaccine recipients followed
 - 827 completed pregnancy
 - 13.9 % loss (same as non-vax population)
 - 9.4 % preterm birth (typically 7.5% nonvax)
 - 3.4 % Small gestational size (same as general population)
- NEJM April 2021

Pregnancy/Covid -19

- No evidence of harm to fetus/baby with SARS-Cov -2
- No evidence of transmission mother to fetus
- SARS Cov2 associated with preterm delivery (3x)
- Pregnant woman 62% more likely to need ICU
 - Nature March 2021

Post Covid Syndrome

- “long Haulers”
 - 10-30 % of Covid-19 patients
 - NOT related to severity of disease
 - Fatigue, dizziness, breathing issues, memory loss
 - Etiology and factors not defined
 - Months post disease
-
- CDC August 2021

Vaccine –Booster

- Immunosuppressed
 - 4 weeks post last dose
- Ab levels decline
 - 6 vs 8 months ?
- J and J vaccine titers remain high
- Awaiting guidance –
- Pfizer likely approved Sept 20,2021

School/Work covid exposure

- Vaccinated individual
 - No quarantine unless symptoms
 - Testing day 5 ,quarantine if positive
- Unvaccinated individuals
 - 14 days quarantine
 - Return work/school 14 days or
 - Return day 7 if negative rapid test day #5 post exposure
- CDC.GOV

Covid testing

- PCR – detects the RNA of virus –
 - 24 hour
 - Highly sensitive
 - “gold standard”
- “antigen” test-AKA rapid test
 - Surface proteins
 - 15 minute
 - Excellent for screening
 - 30% false negative rate

Covid -19 infected persons

- Isolate 10 days from first symptoms
- Do not need a negative test
- If immune disease/cancer isolate 20 days
- Natural disease Ab levels lower than vaccine levels
- Get vaccinated--- 4-6 weeks post disease

Covid- activities of risk

- Dining out- the highest risk event -50 % of new cases
 - Outdoors best
 - Indoors-masks, vaccinated only
 - Low numbers
- Air travel- moderate risk
 - Mask , hand washing/solutions , no eating
- Events
 - Outdoors ideal
 - Refrain from large indoor events
 - “ only vaccinated” –still risk, lower

Covid -19

- Disease of the unvaccinated and children
- Vaccinated remain at risk for disease-host issues
- Pregnancy clearly at high risk for progression of disease
- Vaccine extremely safe
- Vaccine likely approved for < 12 by December
- Long term effects of covid not known yet

Delaware Judiciary COVID-19 measures

- As of Aug. 16, 2021, mask use – covering nose and mouth – was restored as a requirement for all visitors and court staff in all court facilities. (The only exceptions are for individuals speaking in a courtroom as part of a court proceeding or for employees in their own office or a social distant work area.)
- Social distancing continues to be encouraged in court facilities along with the use of plexiglass barriers that were installed during the pandemic, particularly in areas where court staff interact with the public and in courtrooms.
- The Chief Justice has continued to urge the use of remote proceedings, developed during the pandemic, when appropriate and possible.
- As of Sept. 13, 2021, court employees must provide proof of vaccination or submit to weekly COVID-19 tests and provide negative result to supervisors.